This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate the effect of bevacizumab on time to tumor progression, response rates and overall survival when added to centuximab plus irinotecan or to cetuximab alone in patients with irinotecan-refractory metastatic colorectal cancer.
Showing the most recent 10 out of 370 publications